Page last updated: 2024-11-05

benzoylhydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzoylhydrazine: inhibits copper-depleted bovine serum amine oxidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11955
CHEMBL ID125369
CHEBI ID38454
SCHEMBL ID83514
SCHEMBL ID1634869
SCHEMBL ID13456686
MeSH IDM0049416

Synonyms (77)

Synonym
HMS1760B05
benzoyl hydrazine
benzoic acid hydrazide
ccris 1287
hydrazid kyseliny benzoove [czech]
ai3-52284
hsdb 2737
einecs 210-363-9
c6h5-co-nh-nh2
CHEBI:38454 ,
benzoic acid, hydrazide
inchi=1/c7h8n2o/c8-9-7(10)6-4-2-1-3-5-6/h1-5h,8h2,(h,9,10
benzohydrazine
nsc644
benzhydrazide
wln: zmr xvq
nsc-644
benzohydrazide
benzoic hydrazide
nsc 644
benzoylhydrazine
benzoyl hydrazide
hydrazine, benzoyl-
613-94-5
benzhydrazide, 98%
STK027207
B0205
CHEMBL125369
AKOS000119810
A15692
A5388
benzohydrazide;benzoylhydrazine
NCGC00248861-01
benzenecarbohydrazide
dtxsid6020149 ,
tox21_200878
NCGC00258432-01
dtxcid60149
cas-613-94-5
benzoylhydrazide
F1099-0052
hydrazid kyseliny benzoove
llw11zwz20 ,
unii-llw11zwz20
FT-0622658
BBL019079
AM20060387
AB00887
benzohydrazide [usp impurity]
azelastine hydrochloride impurity a [ep impurity]
benzhydrazide [hsdb]
SCHEMBL83514
benzenehydrazide
n-benzoyl hydrazine
SCHEMBL1634869
SCHEMBL13456686
benzenecarboxylic acid hydrazide
n-aminobenzamide
isoniazid, antibiotic for culture media use only
Q-201256
CS-W017759
wm4 ,
mfcd00007596
azelastine impurity a
benzoyldiazane (benzohydrazide)
azelastine hydrochloride imp. a (ep); azelastine imp. a (ep); benzoyldiazane; benzohydrazide; azelastine hydrochloride impurity a; azelastine impurity a
benzoylhydrazone
Z56926669
benzoic acid hydrazone
106731-53-7
Q27117861
AS-14648
BCP26784
EN300-17420
n-benzoylhydrazine
[4-(1h-pyrazol-1-yl)phenyl]aceticacid
hydrazono, benzoyl- (9ci)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency39.89520.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency31.48100.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.95520.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency40.78380.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency15.77110.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.63810.001530.607315,848.9004AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency31.48100.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.13410.000229.305416,493.5996AID1259244; AID1259248; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency16.24530.000723.06741,258.9301AID743085; AID743122
histone deacetylase 9 isoform 3Homo sapiens (human)Potency61.05600.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency12.53280.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency12.53280.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1059234Lipophilicity, log P of the compound2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1059231Antitubercular activity against Mycobacterium tuberculosis2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID143262Minimum inhibitory concentration against Mycobacterium tuberculosis var. bovis strain at 310K, with value expressed as pMIC i.e. -log of MIC (ug/mL).2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.33)18.7374
1990's4 (11.11)18.2507
2000's9 (25.00)29.6817
2010's18 (50.00)24.3611
2020's2 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.45 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]